Aileron Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

Aileron Therapeutics to Report Second Quarter 2019 Financial Results on August 6, 2019

Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy

Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach

Aileron Therapeutics to Present at the Jefferies 2019 Healthcare Conference

Aileron Therapeutics Reports First Quarter 2019 Financial Results

Aileron Therapeutics to Report First Quarter 2019 Financial Results on May 8

Aileron Therapeutics Completes $26M Private Placement

Aileron Therapeutics Announces Pricing of $26M Private Placement

Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer